Document is current
Any future updates will be listed below
-
Authors
Das, Sanjay https://orcid.org/0000-0001-8520-5280
Friedrich, Nadine A. https://orcid.org/0000-0002-6713-0614
Daniels, James https://orcid.org/0000-0002-2401-2474
Galvan, G. Cecilia https://orcid.org/0000-0001-5892-3340
Gong, Jun https://orcid.org/0000-0001-8713-1406
Posadas, Edwin https://orcid.org/0000-0001-8649-1346
Aronson, William https://orcid.org/0000-0003-2107-5362
Freedland, Stephen J. https://orcid.org/0000-0002-8104-6419
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA251072, T32CA240172, TL1 DK132768, U2C DK 129496)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Defense (W81XWH-19-1-0748)
Prostate Cancer Foundation
American Cancer Society (RSG-18-018-01-CPHPS)
- License Information
-
More Information
Article History
Received: 15 March 2023
Revised: 27 July 2023
Accepted: 18 August 2023
First Online: 8 September 2023
Competing interests
: SJF – consultant for Bayer, Astellas, Astra Zeneca, Janssen, Pfizer, Merck, Sanofi and speaker for Astra Zeneca and Sanofi. EP – receives research funding from Pfizer/Astellas, speaker for Bayer and Myovant, advisor for Bayer and Janssen. JG – Consultant for Janssen, Myovant, Astellas, Pfizer, Bayer, Elsevier, Exelixis, and Incyte. WA – Consultant for Bayer, Janssen, Pfizer, Astellas, Myovant. The other authors declare no competing interests.
